For emerging pharma, launching a first product is a milestone that triggers a cascade of operational decisions. How your product reaches the patient doesn’t just shape commercial success; it dictates the organizational infrastructure and operations you must establish.

Business assumptions and data inputs are necessary assets for Gross-to-Net forecasting. For pre-launch products, obtaining these data sets and assumptions is often challenging. Here are some best practices to consider.

Emerging pharmaceutical companies often underestimate the extensive preparation required before a drug launch. Effective pre-launch...